On Feb 23, 2022, STAT Trials Pulse powered Applied XL detected a clinical trial for TG Therapeutics’ drug, umbralisib, unexpectedly stopping early due to safety issues — 51 days before the company publicly announced its voluntary withdrawal of umbralisib’s drug application and the dissolution of its oncology program. For biotech…

Navigating information overload effectively Feldan Therapeutics is a biopharmaceutical company that specializes in developing treatments based on the intracellular delivery of therapeutics. Put simply, the company has developed a proprietary technology that enables the safe and efficient delivery of various therapeutics inside cells. …

New York, N.Y. (March 21, 2022) — Applied XL, a real-time information company tracking disruptions to the health of people, places, and the planet, today announced it had raised $3.5 million in seed funding led by Hearst Ventures with the participation of the Boston Globe Media Partners and STAT, (which…

Today we are thrilled to unveil a new product that has been under development for over a year and that we believe will transform how readers like you track and analyze clinical trials data: STAT Trials Pulse. Developed by artificial intelligence company Applied XL, in conjunction with STAT’s national biotech…

A new algorithm, developed by machine learning company Applied XL, identifies important signals in clinical trials data. Now, life sciences professionals can access this model through STAT Trials Pulse. What if you could be alerted when several trials in a particular class of drugs stopped early due to efficacy issues…